Answers are grounded in this paper and cite their sources.
Mirabegron is the first β3-adrenoreceptor (AR) agonist which was approved for the treatment of overactive bladder (OAB) in the United States, Japan, the European Union, and Canada at a dose of 50 m...
No takes yet. Share an insight, caveat, or question.
Vojtěch Hainer (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: